BRPI0412153B8 - anticorpo monoclonal e fragmento de ligação a antígeno do anticorpo monoclonal - Google Patents

anticorpo monoclonal e fragmento de ligação a antígeno do anticorpo monoclonal

Info

Publication number
BRPI0412153B8
BRPI0412153B8 BRPI0412153A BRPI0412153A BRPI0412153B8 BR PI0412153 B8 BRPI0412153 B8 BR PI0412153B8 BR PI0412153 A BRPI0412153 A BR PI0412153A BR PI0412153 A BRPI0412153 A BR PI0412153A BR PI0412153 B8 BRPI0412153 B8 BR PI0412153B8
Authority
BR
Brazil
Prior art keywords
antibody
monoclonal antibody
activity
binding fragment
methods
Prior art date
Application number
BRPI0412153A
Other languages
English (en)
Portuguese (pt)
Inventor
Moretta Alessandro
Gauthier Laurent
Della Chiesa Mariella
Andre Pascale
Andreas Nicolai Reumert Wagtmann Peter
Berg Padkjaer Soren
Original Assignee
Innate Pharma Sas
Novo Nordisk As
Univ Of Genoa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma Sas, Novo Nordisk As, Univ Of Genoa filed Critical Innate Pharma Sas
Publication of BRPI0412153A publication Critical patent/BRPI0412153A/pt
Publication of BRPI0412153B1 publication Critical patent/BRPI0412153B1/pt
Publication of BRPI0412153B8 publication Critical patent/BRPI0412153B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
BRPI0412153A 2003-07-02 2004-07-01 anticorpo monoclonal e fragmento de ligação a antígeno do anticorpo monoclonal BRPI0412153B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48389403P 2003-07-02 2003-07-02
US60/483,984 2003-07-02
US54547104P 2004-02-19 2004-02-19
US60/545,471 2004-02-19
PCT/DK2004/000470 WO2005003168A2 (en) 2003-07-02 2004-07-01 Methods for the production and cytotoxicity evaluation of kir2dl nk-receptor antibodies

Publications (3)

Publication Number Publication Date
BRPI0412153A BRPI0412153A (pt) 2006-08-22
BRPI0412153B1 BRPI0412153B1 (pt) 2019-07-30
BRPI0412153B8 true BRPI0412153B8 (pt) 2021-05-25

Family

ID=33567703

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0412138A BRPI0412138B8 (pt) 2003-07-02 2004-07-01 método de selecionar um anticorpo monoclonal, método de selecionar um anticorpo monoclonal ou seu fragmento de ligação em antígeno, método de detectar a presença de células nk, e, método de purificar de uma amostra células nk
BRPI0412153A BRPI0412153B8 (pt) 2003-07-02 2004-07-01 anticorpo monoclonal e fragmento de ligação a antígeno do anticorpo monoclonal

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0412138A BRPI0412138B8 (pt) 2003-07-02 2004-07-01 método de selecionar um anticorpo monoclonal, método de selecionar um anticorpo monoclonal ou seu fragmento de ligação em antígeno, método de detectar a presença de células nk, e, método de purificar de uma amostra células nk

Country Status (21)

Country Link
US (2) US9902936B2 (OSRAM)
EP (3) EP2289939B1 (OSRAM)
JP (5) JP5015592B2 (OSRAM)
KR (5) KR101444717B1 (OSRAM)
CN (2) CN103588880B (OSRAM)
AT (1) ATE490984T1 (OSRAM)
AU (2) AU2004253770C1 (OSRAM)
BR (2) BRPI0412138B8 (OSRAM)
CA (2) CA2530272C (OSRAM)
CY (1) CY1113394T1 (OSRAM)
DE (1) DE602004030464D1 (OSRAM)
DK (2) DK1639013T3 (OSRAM)
ES (2) ES2393485T3 (OSRAM)
HR (1) HRP20120845T1 (OSRAM)
IL (3) IL172613A (OSRAM)
MX (1) MXPA05013923A (OSRAM)
NO (4) NO338818B1 (OSRAM)
PL (1) PL1639013T3 (OSRAM)
PT (1) PT1639013E (OSRAM)
RU (2) RU2376315C2 (OSRAM)
WO (2) WO2005003172A2 (OSRAM)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090191213A9 (en) * 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
CA2532547C (en) 2003-07-24 2020-02-25 Innate Pharma Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds
WO2005105849A1 (en) * 2004-04-30 2005-11-10 Innate Pharma Compositions and methods for treating proliferative disorders such as nk-type ldgl
ES2360467T3 (es) * 2004-07-01 2011-06-06 Novo Nordisk A/S Anticuerpos que se unen a receptores kir2dl1, -2, -3 pero no a kir2ds4 y su uso terapéutico.
CA2601417C (en) * 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
WO2006023148A2 (en) 2004-07-10 2006-03-02 Fox Chase Cancer Center Genetically modified human natural killer cell lines
WO2006050270A2 (en) * 2004-11-02 2006-05-11 The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services Compositions and methods for treating hyperproliferative disorders
JP5855326B2 (ja) * 2005-01-06 2016-02-09 ノヴォ ノルディスク アー／エス 抗ｋｉｒ組み合わせ治療および方法
JP5154949B2 (ja) 2005-01-06 2013-02-27 ノヴォ ノルディスク アー／エス ウイルス感染を治療するための組成物および方法
EP1836225B1 (en) 2005-01-06 2011-11-02 Novo Nordisk A/S Kir-binding agents and methods of use thereof
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
EP2322557B1 (en) 2005-10-14 2017-08-30 Innate Pharma Compositions and methods for treating proliferative disorders
EP2109460B1 (en) 2007-01-11 2016-05-18 Novo Nordisk A/S Anti-kir antibodies, formulations, and uses thereof
US8709411B2 (en) 2008-12-05 2014-04-29 Novo Nordisk A/S Combination therapy to enhance NK cell mediated cytotoxicity
WO2010076788A2 (en) * 2008-12-29 2010-07-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
US20120308986A1 (en) * 2010-02-08 2012-12-06 Biotherapy Institute Of Japan Method for producing nk cell-enriched blood product
CN106963947A (zh) 2010-11-22 2017-07-21 伊纳特医药股份有限公司 Nk细胞调节治疗和用于治疗血液恶性疾病的方法
AU2012260601B2 (en) 2011-05-25 2018-02-01 Innate Pharma, S.A. Anti-KIR antibodies for the treatment of inflammatory disorders
EP2723362A1 (en) 2011-06-21 2014-04-30 Innate Pharma NKp46-MEDIATED NK CELL TUNING
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
CN103946236B (zh) * 2011-11-23 2018-02-16 弗·哈夫曼-拉罗切有限公司 表达cd40l的哺乳动物细胞及其用途
AU2013320360B2 (en) * 2012-09-19 2018-06-14 Innate Pharma KIR3DL2 binding agents
SG10201702421TA (en) 2012-10-02 2017-05-30 Bristol Myers Squibb Co Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
WO2015069785A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
EP3187583B1 (en) * 2014-08-29 2023-04-26 National University Corporation Hokkaido University Monoclonal antibody against kir2ds1
ES2772307T3 (es) 2014-10-28 2020-07-07 Childrens Univ Hospital Tuebingen Tratamiento de pacientes pediátricos con LLA-PCB con un anticuerpo anti-kir
PL3253865T3 (pl) 2015-02-06 2022-10-10 National University Of Singapore Sposoby wzmacniania skuteczności terapeutycznych komórek odpornościowych
KR102740444B1 (ko) 2015-04-17 2024-12-10 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
NZ738068A (en) 2015-05-06 2019-07-26 Snipr Tech Ltd Altering microbial populations & modifying microbiota
EP3932428A1 (en) 2015-05-21 2022-01-05 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
CA3004138A1 (en) * 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and tim-3 and their uses
CA3004530A1 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN115350263A (zh) 2016-05-20 2022-11-18 拜尔哈文制药股份有限公司 谷氨酸调节剂与免疫疗法用以治疗癌症的用途
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
US20190233534A1 (en) 2016-07-14 2019-08-01 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
MX2019003447A (es) 2016-09-27 2019-08-29 Univ Texas Metodos para mejorar la terapia de bloqueo del punto de control inmune mediante la modulacion del microbioma.
CN116672456A (zh) 2016-10-12 2023-09-01 得克萨斯州大学系统董事会 用于tusc2免疫治疗的方法和组合物
CA3037851A1 (en) 2016-10-21 2018-04-26 Innate Pharma Treatment with anti-kir3dl2 agents
KR20190112263A (ko) 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
US20210101980A1 (en) 2017-03-31 2021-04-08 Bristol-Myers Squibb Company Methods of treating tumor
AU2018248672B2 (en) 2017-04-05 2021-09-30 Korea Research Institute Of Bioscience And Biotechnology NK cell-activating fusion protein, NK cell, and pharmaceutical composition including same
KR102376863B1 (ko) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. 메소텔린 결합 단백질
WO2018218207A1 (en) 2017-05-26 2018-11-29 Fred Hutchinson Cancer Research Center Anti-cd33 antibodies and uses thereof
CN107261304A (zh) * 2017-06-05 2017-10-20 中国兽医药品监察所 一种奶牛的布鲁氏菌病免疫试剂盒及其应用
SG11202000402PA (en) 2017-08-10 2020-02-27 Nat Univ Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CN111630070B (zh) 2017-10-13 2024-07-30 哈普恩治疗公司 三特异性蛋白质及使用方法
WO2019075468A1 (en) 2017-10-15 2019-04-18 Bristol-Myers Squibb Company TUMOR TREATMENT METHODS
CN108060137B (zh) * 2017-12-26 2021-07-02 博生吉医药科技(苏州)有限公司 Il7和il21修饰的nk92细胞、制备方法及其应用
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
PE20210375A1 (es) 2018-02-08 2021-03-02 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
FI3749346T3 (fi) 2018-02-08 2024-09-04 Dragonfly Therapeutics Inc Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
MX2020008684A (es) 2018-02-20 2020-12-07 Dragonfly Therapeutics Inc Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso.
US12454561B2 (en) 2018-03-19 2025-10-28 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
KR102761890B1 (ko) 2018-03-23 2025-02-06 브리스톨-마이어스 스큅 컴퍼니 Mica 및/또는 micb에 대한 항체 및 그의 용도
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
JP7761995B2 (ja) 2018-03-25 2025-10-29 エスエヌアイピーアール・バイオーム・アーペーエス 微生物感染症の治療及び予防
JP2021519771A (ja) 2018-03-30 2021-08-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍を処置する方法
AU2019275076B2 (en) 2018-05-23 2024-12-19 National University Of Singapore Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies
US12384851B2 (en) 2018-08-08 2025-08-12 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
JP7482363B2 (ja) 2018-08-08 2024-05-14 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質
EP3849565A4 (en) 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
US20220054524A1 (en) 2018-12-21 2022-02-24 Onxeo New conjugated nucleic acid molecules and their uses
JP2022534981A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよび組み合わせ治療
CN114127315A (zh) 2019-05-30 2022-03-01 百时美施贵宝公司 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
CN111424012A (zh) * 2020-03-30 2020-07-17 威海市中心医院 一种nk细胞培养用的饲养细胞去增殖能力的处理方法
TW202208428A (zh) 2020-05-06 2022-03-01 美商蜻蜓醫療公司 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
MX2023002326A (es) 2020-08-31 2023-03-21 Bristol Myers Squibb Co Firma de localizacion celular e inmunoterapia.
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
US20240000837A1 (en) * 2020-12-23 2024-01-04 H. Lee Moffitt Cancer Center And Research Institute Inc. Inhibition of kir2dl2 for the enhancement of adoptive immunotherapies
WO2022146948A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
AU2021411486A1 (en) 2020-12-28 2023-06-29 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
MX2023009100A (es) 2021-02-03 2023-09-25 Mozart Therapeutics Inc Agentes aglutinantes y métodos para usar los mismos.
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
MX2024004082A (es) 2021-10-08 2024-04-18 3M Innovative Properties Company Montaje de troquel de ranura con rigidez ajustada, zona de extraccion reducida y estimacion de fuerza.
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023110937A1 (en) 2021-12-14 2023-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
IL313439A (en) 2021-12-16 2024-08-01 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
US20250332252A1 (en) 2022-06-02 2025-10-30 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
WO2024026385A1 (en) * 2022-07-28 2024-02-01 H. Lee Moffitt Cancer Center And Research Institute Inc. Inhibition of kir2dl2 and/or kir2dl3 for the enhancement of adoptive immunotherapies
TW202426486A (zh) * 2022-10-25 2024-07-01 日商第一三共股份有限公司 使用針對抑制型ｋｉｒ的促效劑的免疫排斥之迴避方法
KR20250120305A (ko) 2022-12-14 2025-08-08 아스텔라스 파마 유럽 비.브이. Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
CN117883553B (zh) * 2024-01-12 2024-08-27 成都医学院 Pml-1蛋白在制备抑制细胞因子风暴的药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5539094A (en) 1993-11-12 1996-07-23 La Jolla Cancer Research Foundation DNA encoding Bcl-2-associated proteins
IL108501A (en) * 1994-01-31 1998-10-30 Mor Research Applic Ltd Antibodies and pharmaceutical compositions containing them
US5583034A (en) 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
US5808028A (en) * 1994-05-24 1998-09-15 The United States Of America As Represented By The Department Of Health And Human Services Molecular clone of a P58 receptor protein and uses thereof
NZ298145A (en) 1994-12-29 1998-08-26 Yamanouchi Pharma Co Ltd Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
JP2002529705A (ja) * 1998-10-29 2002-09-10 コンネクス・ゲーエムベーハー 糞便中の耐酸性微生物を検出するための新規方法
CA2372053C (en) 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
KR100419555B1 (ko) * 2000-05-29 2004-02-19 주식회사유한양행 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
CA2532547C (en) * 2003-07-24 2020-02-25 Innate Pharma Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds
CA2601417C (en) 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
PT1831258E (pt) * 2004-12-28 2016-01-07 Univ Genova Anticorpos monoclonais contra nkg2a
EP1836225B1 (en) * 2005-01-06 2011-11-02 Novo Nordisk A/S Kir-binding agents and methods of use thereof
JP5154949B2 (ja) * 2005-01-06 2013-02-27 ノヴォ ノルディスク アー／エス ウイルス感染を治療するための組成物および方法
JP5855326B2 (ja) * 2005-01-06 2016-02-09 ノヴォ ノルディスク アー／エス 抗ｋｉｒ組み合わせ治療および方法
EP2322557B1 (en) * 2005-10-14 2017-08-30 Innate Pharma Compositions and methods for treating proliferative disorders
EP2109460B1 (en) 2007-01-11 2016-05-18 Novo Nordisk A/S Anti-kir antibodies, formulations, and uses thereof
AU2012260601B2 (en) * 2011-05-25 2018-02-01 Innate Pharma, S.A. Anti-KIR antibodies for the treatment of inflammatory disorders
US9789182B2 (en) * 2012-10-23 2017-10-17 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
WO2015069785A1 (en) * 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
US9884593B2 (en) * 2015-02-12 2018-02-06 Pro-Gard Products, Llc Weapon mounting system

Also Published As

Publication number Publication date
KR101375153B1 (ko) 2014-03-18
AU2004253630B2 (en) 2010-11-25
US9902936B2 (en) 2018-02-27
AU2004253770A1 (en) 2005-01-13
BRPI0412138B8 (pt) 2021-05-25
ATE490984T1 (de) 2010-12-15
AU2004253630A1 (en) 2005-01-13
JP2018153185A (ja) 2018-10-04
HK1091662A1 (en) 2007-01-26
EP2289939A3 (en) 2013-12-04
PL1639013T3 (pl) 2013-02-28
NO343342B1 (no) 2019-02-04
EP2289939A2 (en) 2011-03-02
BRPI0412138A (pt) 2006-08-15
WO2005003172A2 (en) 2005-01-13
CA2530272C (en) 2018-05-01
WO2005003168A2 (en) 2005-01-13
CN103588880B (zh) 2019-09-17
WO2005003168A3 (en) 2005-05-06
JP2007524612A (ja) 2007-08-30
KR20120024998A (ko) 2012-03-14
CA2530591A1 (en) 2005-01-13
DK1673397T3 (da) 2011-03-07
NO20060528L (no) 2006-02-01
NO20160264A1 (no) 2016-02-16
MXPA05013923A (es) 2006-08-11
KR20060079180A (ko) 2006-07-05
US20180216069A1 (en) 2018-08-02
WO2005003172A3 (en) 2005-03-10
EP1639013A2 (en) 2006-03-29
KR101325023B1 (ko) 2013-11-04
RU2404993C2 (ru) 2010-11-27
JP2015163068A (ja) 2015-09-10
JP5826697B2 (ja) 2015-12-02
IL172700A0 (en) 2006-04-10
HRP20120845T1 (hr) 2012-11-30
BRPI0412138B1 (pt) 2021-01-26
KR20120059659A (ko) 2012-06-08
NO338255B1 (no) 2016-08-08
KR101420344B1 (ko) 2014-07-16
KR20060111440A (ko) 2006-10-27
JP2012176953A (ja) 2012-09-13
CN103588880A (zh) 2014-02-19
US11365393B2 (en) 2022-06-21
RU2005140152A (ru) 2007-08-27
IL238490A0 (en) 2015-06-30
EP1639013B1 (en) 2012-09-12
AU2004253770B2 (en) 2009-10-29
PT1639013E (pt) 2012-12-03
EP1673397A2 (en) 2006-06-28
CN103467602A (zh) 2013-12-25
BRPI0412153A (pt) 2006-08-22
CN103467602B (zh) 2018-04-10
NO338818B1 (no) 2016-10-24
NO342318B1 (no) 2018-05-07
KR20130062379A (ko) 2013-06-12
EP1673397B1 (en) 2010-12-08
JP5015592B2 (ja) 2012-08-29
ES2393485T3 (es) 2012-12-21
AU2004253770C1 (en) 2010-04-15
KR101444717B1 (ko) 2014-09-26
JP2008500947A (ja) 2008-01-17
NO20056048L (no) 2006-04-03
NO20160411A1 (no) 2016-03-10
RU2376315C2 (ru) 2009-12-20
EP2289939B1 (en) 2019-03-27
DK1639013T3 (da) 2013-01-07
ES2725526T3 (es) 2019-09-24
CA2530272A1 (en) 2005-01-13
RU2006102960A (ru) 2006-06-27
IL172700A (en) 2015-05-31
US20060263361A1 (en) 2006-11-23
IL172613A (en) 2010-12-30
BRPI0412153B1 (pt) 2019-07-30
JP4871125B2 (ja) 2012-02-08
DE602004030464D1 (de) 2011-01-20
IL172613A0 (en) 2006-04-10
JP6556465B2 (ja) 2019-08-07
CY1113394T1 (el) 2016-06-22

Similar Documents

Publication Publication Date Title
BRPI0412153B8 (pt) anticorpo monoclonal e fragmento de ligação a antígeno do anticorpo monoclonal
Michishita et al. Cell cycle-dependent deacetylation of telomeric histone H3 lysine K56 by human SIRT6
Minkiewicz et al. Human astrocytes express a novel NLRP2 inflammasome
Silva Valvassori et al. Sodium butyrate functions as an antidepressant and improves cognition with enhanced neurotrophic expression in models of maternal deprivation and chronic mild stress
Kim et al. Mechanisms and potential therapeutic applications of microglial activation after brain injury
Weinstein et al. Lipopolysaccharide-induced protein tyrosine phosphorylation in human macrophages is mediated by CD14.
BRPI0821658B8 (pt) anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos
Rattan Anti‐ageing strategies: prevention or therapy? Slowing ageing from within
BR112013017446A2 (pt) composição, uso de dose baixa de pioglitazona, método de tratar a deterioração cognitiva do tipo de alzheimer em um indivíduo humano, de tratar o declínio cognitivo em um indivíduo humano, de determinar o risco aumentado de desenvolver a deterioração cognitiva do tipo de alzheimer em um indivíduo humano em uma uma idade ou faixa de idade pré-determinadas, de determinar se administrar dose baixa de pioglitazona a um indivíduo humano para o tratamento da deterioração congnitiva do tipo de alzheimer, de retardar o início da doença de alzheimer em um indivíduo em risco de desenvolver a doença alzheimer, de retardar o início da deterioração cognitiva amnésia branda em um indivíduo em risco de desenvolver a doença de alzheimer, de retardar o início da doença de alzheimer pré-clínica em um indivíduo em risco de desenvolver a doença de alzheimer, de retardar o início da doença de alzheimer pródroma em um indivíduo em risco de desenvolver a doença de alzheimer, dose baixa de pioglitazona
Kim et al. Low-dose radiation stimulates the proliferation of normal human lung fibroblasts via a transient activation of Raf and Akt
Bindu et al. Prophylactic and therapeutic insights into trained immunity: A renewed concept of innate immune memory
Chang et al. Molecular mechanisms in the initiation phase of Wallerian degeneration
Ghisoni et al. Neopterin acts as an endogenous cognitive enhancer
Hwang et al. Induction of pro-inflammatory cytokines by 29-kDa FN-f via cGAS/STING pathway
Li et al. Quercetin as a promising intervention for rat osteoarthritis by decreasing M1‐polarized macrophages via blocking the TRPV1‐mediated P2X7/NLRP3 signaling pathway
Leitner et al. Anti-Inflammatory extract from soil algae Chromochloris zofingiensis Targeting TNFR/NF-κB Signaling at different levels
Jiang et al. Curcumin inhibits the pruritus in mice through mast cell MrgprB2 receptor
Song et al. Gossypol suppresses mouse T lymphocytes via inhibition of NFκB, NFAT and AP-1 pathways
Kang et al. Genkwadaphnin induces IFN-γ via PKD1/NF-κB/STAT1 dependent pathway in NK-92 cells
BR112022021203A2 (pt) Modulação de enzima e via com compostos sulfidrila e seus derivados
Rodrigues et al. A1. 1 Obesity is a risk factor for worse treatment response in rheumatoid arthritis patients-results from reuma. pt
BRPI0516661A (pt) epitopos antigênicos da interleucina-21, anticorpos relacionados e seu uso no campo medicinal
Park et al. 7, 8-dihydroxyflavone induces G1 arrest of the cell cycle in U937 human monocytic leukemia cells via induction of the Cdk inhibitor p27 and downregulation of pRB phosphorylation
Kallinich Regulating against the dysregulation: new treatment options in autoinflammation
Zhong et al. The role of deoxycytidine kinase (dCK) in radiation-induced cell death

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/07/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2834 DE 29/04/2025 POR TER SIDO INDEVIDA.